Sumitomo Mitsui Trust Group Inc. trimmed its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 9.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 142,433 shares of the company's stock after selling 14,224 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.09% of Ionis Pharmaceuticals worth $4,297,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC increased its position in shares of Ionis Pharmaceuticals by 3,786.5% during the 1st quarter. GAMMA Investing LLC now owns 28,993 shares of the company's stock worth $961,000 after purchasing an additional 28,247 shares during the last quarter. Commonwealth Equity Services LLC grew its position in Ionis Pharmaceuticals by 1.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 21,826 shares of the company's stock valued at $763,000 after acquiring an additional 373 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Ionis Pharmaceuticals by 11.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 10,994 shares of the company's stock valued at $384,000 after acquiring an additional 1,101 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in Ionis Pharmaceuticals in the 4th quarter valued at about $829,000. Finally, Fifth Third Bancorp grew its position in Ionis Pharmaceuticals by 4.8% in the 1st quarter. Fifth Third Bancorp now owns 9,989 shares of the company's stock valued at $301,000 after acquiring an additional 458 shares in the last quarter. 93.86% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Ionis Pharmaceuticals news, Director Michael R. Hayden acquired 15,000 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The shares were purchased at an average price of $31.86 per share, with a total value of $477,900.00. Following the completion of the acquisition, the director directly owned 50,219 shares of the company's stock, valued at approximately $1,599,977.34. The trade was a 42.59% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 2.71% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Several research firms have weighed in on IONS. Needham & Company LLC dropped their target price on Ionis Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Redburn Atlantic began coverage on Ionis Pharmaceuticals in a research report on Monday, March 31st. They issued a "neutral" rating and a $39.00 target price for the company. Wall Street Zen raised Ionis Pharmaceuticals to a "sell" rating in a research report on Tuesday, March 18th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Ionis Pharmaceuticals in a research report on Thursday, June 26th. Finally, Guggenheim decreased their price objective on Ionis Pharmaceuticals from $65.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Two research analysts have rated the stock with a sell rating, three have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Ionis Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $58.25.
View Our Latest Report on Ionis Pharmaceuticals
Ionis Pharmaceuticals Stock Performance
NASDAQ IONS traded down $1.22 on Monday, reaching $41.78. The stock had a trading volume of 2,239,880 shares, compared to its average volume of 1,607,462. The stock has a market cap of $6.65 billion, a P/E ratio of -13.97 and a beta of 0.23. The company has a debt-to-equity ratio of 2.63, a quick ratio of 9.62 and a current ratio of 9.66. The business's 50-day moving average price is $35.48 and its 200 day moving average price is $33.14. Ionis Pharmaceuticals, Inc. has a 12-month low of $23.95 and a 12-month high of $52.34.
Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.14. The business had revenue of $132.00 million for the quarter, compared to analyst estimates of $144.31 million. Ionis Pharmaceuticals had a negative return on equity of 91.85% and a negative net margin of 63.65%. The company's revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.98) earnings per share. As a group, equities analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.
Ionis Pharmaceuticals Profile
(
Free Report)
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
Featured Articles

Before you consider Ionis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.
While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.